title: Other PET Tracers and Prospects for the Future.
abstract: (18)F FDG-PET has proven its use as a technique in the field of melanoma, but there are valid concerns related to the specificity of (18)F FDG-PET findings and the degree of accuracy we can expect in the assessment of response to new treatment protocols. The main avenues currently being explored for future use in staging and management of melanoma with PET other than FDG include monoclonal antibodies against melanoma-associated antigens, α-MSH analogues, amino acids involved in melanin formation, nicotinamide-based compounds, heterodimeric glycoproteins such as integrins, reporter gene imaging, cell proliferation, and hypoxia tracers.
authors.affiliation: Nuclear Medicine Department, Hospital Clínic of Barcelona, Villarroel 170, 08036 Barcelona, Spain.
authors.forename: David
authors.initials: D
authors.lastname: Fuster
authors.affiliation: Nuclear Medicine Department, Hospital Clínic of Barcelona, Villarroel 170, 08036 Barcelona, Spain.
authors.forename: Francesca
authors.initials: F
authors.lastname: Pons
authors.affiliation: Department of Nuclear Medicine, PET/CT Center, Santa Maria della Misericordia Hospital, Via Tre Martiri 140, 45100, Rovigo, Italy.
authors.forename: Domenico
authors.initials: D
authors.lastname: Rubello
authors.affiliation: Department of Radiology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
authors.forename: Abass
authors.initials: A
authors.lastname: Alavi